Cap tables get crowded
Traditional rounds often add dozens of direct investors—slow closes, heavy admin, and messy follow-on rights.
Invite-only · Precision Diligence
Biopharma's invite-only investment syndicate.
We vet each opportunity with Precision Diligence and bring it to a trusted network of accredited biopharma investors. Founders get a clean cap table; investors get limited liability and deals worth their time.
Reg D · accredited investors only
Precision Diligence built in
Who it's for
Dedicated structure per deal
Each raise runs in its own workspace—clean capital pooling, limited liability, and streamlined investor reporting.
For founders raising a roundFirst deal free
- Matched, not blasted—Accredited investors see deals matched on stage, modality, and network—not a public marketplace blast.
- Diligence before you're shown—Precision Diligence and team review before your opportunity is opened to the network.
For accredited investors
- Curated, accredited-only flow—Reg D 506(c) only. After verification, review opportunities matched to your focus.
- Precision Diligence on every deal—Investor-ready synthesis on each published opportunity—not marketing copy.
Invite-only · Precision Diligence. Reg D workflows and BioSyndex Precision Diligence on every listing. See how it works or scroll to compare paths for companies and investors.
For founders raising a round
Raise from a curated biopharma network.
Your first deal lists free as a founding issuer. After Precision Diligence and approval, accredited investors commit through the platform. You get one wire and one line on your cap table — not 30 individual shareholders.
- Matched, not blasted — Accredited investors see deals matched on stage, modality, and network—not a public marketplace blast.
- Diligence before you're shown — Precision Diligence and team review before your opportunity is opened to the network.
For accredited investors
Vetted biopharma deals.
Reg D 506(c) only. After verification, review opportunities matched to your focus and co-invest alongside people you trust . Free to participate, always.
- Curated, accredited-only flow — Reg D 506(c) only. After verification, review opportunities matched to your focus.
- Precision Diligence on every deal — Investor-ready synthesis on each published opportunity—not marketing copy.
The problem
Capital formation in biopharma still moves too slowly.
Syndication stays fragmented
Warm introductions live in inboxes and spreadsheets, so momentum is hard to see and harder to repeat deal to deal.
Compliance adds friction
Reg D 506(c) rules and accreditation checks are essential but painful when every deal is wired differently.
The solution
One workspace for each raise — BioSyndex Precision Diligence
Structured issuer diligence and an investor-ready synthesis report before a deal is published to the network.
- 1Apply & clear diligence
A company applies or is invited. We run Precision Diligence and team review before the opportunity is opened to the network.
- 2Get matched
Accredited investors see deals matched on stage, modality, and network—not a generic blast list.
- 3Invite & commit
Verified investors co-invest alongside trusted leads through our broker-dealer partner—following each deal's definitive documents.
- 4Close & report
When the raise reaches its target, funds flow to the company; members receive updates and tax reporting on a pro-rata basis.
BioSyndex Precision Diligence is our structured evaluation of each opportunity—drawing on 100+ regulatory, financial, and scientific sources (powered by Katogen's diligence tooling)—and producing an investor-ready synthesis before a deal is published to the network.
Why BioSyndex
Why teams use BioSyndex
Structured issuer diligence and an investor-ready synthesis report before a deal is published to the network.
One SPV per deal
Every opportunity is syndicated through its own ring-fenced vehicle—clean pooling, limited liability, and one K-1 per deal for investors.
Reg D 506(c) compliance layer
Accredited-investor verification, invite-only access, and no broad public solicitation.
BioSyndex Precision Diligence
Structured issuer diligence and an investor-ready synthesis report before a deal is published to the network.
Features
Tools to run a raise with less friction
Structured issuer diligence and an investor-ready synthesis report before a deal is published to the network.
BioSyndex Precision Diligence
BioSyndex Precision Diligence is our structured evaluation of each opportunity—drawing on 100+ regulatory, financial, and scientific sources (powered by Katogen's diligence tooling)—and producing an investor-ready synthesis before a deal is published to the network.
Dedicated structure per deal
Each raise runs in its own workspace—clean capital pooling, limited liability, and streamlined investor reporting.
Reg D 506(c) compliance layer
Accredited-investor verification, invite-only access, and no broad public solicitation.
BioSyndex Precision Diligence
Structured issuer diligence and an investor-ready synthesis report before a deal is published to the network.
Invite-only syndication
Issuers and leads bring trusted co-investors into each raise—high-signal growth without a noisy marketplace.
Managed offering administration
BioSyndex Advisors LLC serves as exempt reporting adviser on offerings; economics and governance are disclosed in each deal's PPM.
One wire for companies
Issuers interact with one counterparty instead of managing dozens of individual investors on the cap table.
Illustrative only
How strong is the investor match?
Sample match scores for demonstration. Each card shows a distinct rationale—stage fit, investor focus, and network overlap.
AtlasGene · Phase II oncology
Series B
Match score91%
Strong stage fit for crossover oncology funds · two warm introductions in network · modality matches investor thesis.
Northwind Bio · ADC platform
Seed extension
Match score84%
Platform play aligned with ADC-focused LPs · geographic overlap with lead syndicate · timing fits diligence calendar.
HelioLattice · radiopharma
Crossover
Match score88%
Radiopharma expertise in investor base · prior co-investment history · regulatory path clear in diligence preview.
Product demo
Watch the 60-second walkthrough
See listing, diligence, syndicate activity, and how SPV-per-deal participation fits together—about one minute.
Leadership
Built by operators who know biopharma capital formation
Doug Drysdale
Founder & CEO, BioSyndex, Inc.
Doug founded BioSyndex around biopharma's invite-only investment syndicate. — combining a curated investor network with BioSyndex Precision Diligence. BioSyndex, Inc. — a Katogen company — drawing on Katogen's diligence tooling and operator experience across regulatory, financial, and scientific evaluation.
BioSyndex Precision Diligence is our structured evaluation of each opportunity—drawing on 100+ regulatory, financial, and scientific sources (powered by Katogen's diligence tooling)—and producing an investor-ready synthesis before a deal is published to the network.
Advisor & network logos — assets pending